Femoral haemostasis after transcatheter therapeutic intervention: a prospective randomised study of the angio-seal device vs. the femostop device.
BACKGROUND
A number of haemostatic devices are available to facilitate early haemostasis following transfemoral interventional procedures.


RESULTS
We have prospectively compared 150 patients (age: 57+/-12 years, mean+/-S.D.) who were randomly assigned to either external compression using the FemoStop device or direct closure of the arterial puncture using the Angio-Seal device. The Angio-Seal was deployed in the catheter laboratory after the conclusion of the procedure. Patients, randomised to FemoStop, had their sheath removed when the activated clotting time (ACT) was less than 100 s before applying the device. The primary endpoint was the composite of bleeding, haematoma formation, bruise, requirement for blood transfusion, clinical indication for ultrasound examination at 2 h and 24 h following the procedure and crossover to either method at 2 and 24 h after the device deployment. The 95% of the Angio-Seal and 96% of FemoStop patients were discharged on the day following the procedure. An increased number of patients in the Angio-Seal group reached a clinical end-point within the first 2 h (45% vs. 3%, P<0.0001). This difference became insignificant at 24 h (25% vs. 30%, P=0.6).


CONCLUSIONS
Although less comfortable, the overall efficacy of the FemoStop appeared to be higher than that of the Angio-Seal device.
Amin
F R
FR
Division of Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, Royal Brompton and Harefield Hospitals, Sydney Street, SW3 6NP, London, UK.
Yousufuddin
M
M
Stables
R
R
Shamim
W
W
Al-Nasser
F
F
Coats
A J
AJ
Clague
J
J
Sigwart
U
U
D002406:Catheterization, Peripheral / Q000009:adverse effects*; D016009:Chi-Square Distribution; D005260:Female; D005263:Femoral Artery; D006489:Hemostatic Techniques / Q000295:instrumentation*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology / Q000517:prevention & control*; D011446:Prospective Studies; D011677:Punctures / Q000009:adverse effects; D012307:Risk Factors